REGENXBIO Inc. (RGNX) is scheduled to report additional interim data from its phase II AAVIATE trial, including full six-month results from Cohorts 5 and 6, at the Hawaiian Eye and Retina meeting today, i.e. January 16, 2024.
AAVIATE is a phase II trial of the company's lead gene therapy program ABBV-RGX-314 using suprachoroidal delivery for the treatment of wet AMD.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com